ArticleNature medicine2023
Intratumoral dendritic cell-CD4
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 286 papers.
0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed
84.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
286 citing papers in PubMed, 367 citations in OpenAlex.
- Integrated single-cell multi-omics characterization reveals lipid-associated macrophage-mediated immunosuppression in neoadjuvant immunotherapy of hepatocellular carcinoma.Nature communications · 2026Trial
- Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Cell reports. Medicine · 2026Trial
- Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.Nature medicine · 2025Trial
- Efficacy and Safety of Erzhu Jiedu Decoction Granules in Treating Mid-advanced Hepatitis B Virus-Associated Primary Liver Cancer Patients with Pi (Spleen)-Deficiency and Dampness-Heat Syndrome.Chinese journal of integrative medicine · 2025Trial
- Distinct CD8Cancer cell · 2025Trial
- Spatial Transcriptomics Analysis of Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027Article
- CXCL13-expressing CD4Oncoimmunology · 2026Article
- NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells.Oncoimmunology · 2026Article
- High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy.International journal of cancer · 2026Article
- CD8⁺ T Cell infiltration and spatial organization in cancer: mechanisms, barriers, and therapeutic strategies.Molecular biomedicine · 2026Review
- Spatial T lymphocyte infiltration into the primary melanoma tumor associates with survival.Melanoma research · 2026Article
- Antibody-lectin chimeras for glyco-immune checkpoint blockade.Nature biotechnology · 2026Article
- Review
- Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer.Molecular carcinogenesis · 2026Article
- Dendritic cell PD-L2 restrains intratumoral CD8bioRxiv : the preprint server for biology · 2026Article
- CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity.The Journal of experimental medicine · 2026Article
- Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote antitumor immunity.Nature cancer · 2026Article
- The multifaceted landscape of T cell exhaustion in organ transplantation: From molecular mechanisms (epigenetics, transcription, metabolism) to induction strategies.Genes & diseases · 2026Review
- Microbiome-Immune Interactions as Determinants of Checkpoint Inhibitor Efficacy in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Review
- Review
226 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 4 institutions in 1 country.
Assaf Magen *The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-5473-274X
Pauline Hamon *The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nathalie FiaschiDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Brian Y SoongThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Matthew D ParkThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Raphaël MattiuzThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3292-1635
Etienne HumblinThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Leanna TroncosoThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-2529-9267
Darwin D'souzaHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Travis DawsonHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-9609-793X
Joel KimThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Steven HamelThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mark BuckupThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Christie ChangThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alexandra TabachnikovaThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hara SchwartzThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nausicaa MalissenThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yonit LavinThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Alessandra Soares-SchanoskiThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bruno GiottiDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Samarth HegdeThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Giorgio IoannouThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Edgar Gonzalez-KozlovaThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6948-0626
Clotilde HennequinThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jessica Le BerichelThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhen ZhaoThe Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stephen C WardThe Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Isabel FielThe Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Baijun KouDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Michael DoboszDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Lianjie LiDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Christina AdlerMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Min NiMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Yi WeiMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Wei WangMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Gurinder S AtwalMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Kunal KunduVI NEXT, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Kamil J CyganVI NEXT, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.ORCID 0000-0003-2088-474X
Alexander M TsankovDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Adeeb RahmanHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Colles PriceVizgen Inc., Cambridge, MA, USA.
Nicolas FernandezVizgen Inc., Cambridge, MA, USA.
Jiang HeVizgen Inc., Cambridge, MA, USA.
Namita T GuptaMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.ORCID 0000-0002-4517-1546
Seunghee Kim-SchulzeThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sacha GnjaticThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-5643-9520
Ephraim KenigsbergThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-4107-3295
Raquel P DeeringDepartment of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Myron SchwartzThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. myron.schwartz@mountsinai.org.ORCID 0000-0002-9113-886X
Thomas U Marron *The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. thomas.marron@mssm.edu.ORCID 0000-0001-5903-8191
Gavin Thurston *Department of Oncology & Angiogenesis, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA. gavin.thurston2000@gmail.com.ORCID 0000-0002-4105-5919
Alice O Kamphorst *The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. alice.kamphorst@mssm.edu.
Miriam Merad *The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Miriam.merad@mssm.edu.ORCID 0000-0002-4481-7827
Icahn School of Medicine at Mount Sinai · USRegeneron (United States) · USTisch Hospital · USRepligen (United States) · US
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0MThe PreVAIL-kIds Common ProtocolR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ALLEN, CARL E, ANNAPRAGADA, ANANTH V · 2023 to 2023
$6.3MInvestigating Macrophage Molecular and Functional Diversity in Tumor ImmunityR01CA254104 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2021 to 2025
$3.4MDissecting the pathways driving progenitor to pro-tumor macrophage programmingR01CA257195 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2021 to 2026
$3.3MDeterminants of differentiation and maintenance of PD-1+ CD8 T cellsR01AI153363 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KAMPHORST, ALICE OLIFFSON · 2021 to 2025
$3.3MCharacterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9MPRIMAVO: Interactive exploration of cancer patient precision immune monitoring data in clinical trialsR33CA263705 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GUMUS, ZEYNEP HULYA · 2021 to 2021
$1.5MDefining the barriers to immune surveillance in solid tumorsK00CA223043 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEGDE, SAMARTH · 2020 to 2023
$374kNCI NIH HHS K00 CA223043NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA154947NCI NIH HHS R01 CA254104NCI NIH HHS R01 CA257195NCI NIH HHS R33 CA263705NCI NIH HHS U24 CA224319NIAID NIH HHS R01 AI153363NICHD NIH HHS R33 HD105593NIDDK NIH HHS U01 DK124165
Abstract
Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T cell rich tumors fail to respond to immune checkpoint blockade (ICB). We leveraged a neoadjuvant anti-PD-1 trial in patients with hepatocellular carcinoma (HCC), as well as additional samples collected from patients treated off-label, to explore correlates of response to ICB within T cell-rich tumors. We show that ICB response correlated with the clonal expansion of intratumoral CXCL13
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsCD8-Positive T-LymphocytesCell DifferentiationDendritic CellsHumansProgrammed Cell Death 1 ReceptorT-Lymphocytes, Helper-InducerProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.